Safety and Efficacy on Spasticity Symptoms of a Cannabis Sativa Extract in Motor Neuron Disease (CANALS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT01776970

Recruitment Status : Completed

First Posted : January 28, 2013

Last Update Posted : March 9, 2017

View this study on Beta.ClinicalTrials.gov

Sponsor:

Collaborators:

Fondazione Salvatore Maugeri

Niguarda Hospital

University of Padova

Information provided by (Responsible Party):

Giancarlo Comi, Ospedale San Raffaele

No Study Results Posted on ClinicalTrials.gov for this Study

About Study Results Reporting on ClinicalTrials.gov

Recruitment Status :	Completed
Actual Primary Completion Date :	December 2015
Actual Study Completion Date :	December 2015

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Riva N, Mora G, Soraru G, Lunetta C, Ferraro OE, Falzone Y, Leocani L, Fazio R, Comola M, Comi G; CANALS Study Group. Safety and efficacy of nabiximols on spasticity symptoms in patients with motor neuron disease (CANALS): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Neurol. 2019 Feb;18(2):155-164. doi: 10.1016/S1474-4422(18)30406-X. Epub 2018 Dec 13.

To Top